Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy

Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini re...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yinghua, Fan, Xiang, Yu, Zhanyang, Liao, Zhengbu, Wang, Xiao-Shu, van Leyen, Klaus, Sun, Xiaochuan, Lo, Eng H., Wang, Xiaoying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604305/
https://www.ncbi.nlm.nih.gov/pubmed/26528130
http://dx.doi.org/10.3389/fncel.2015.00397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604305/
https://www.ncbi.nlm.nih.gov/pubmed/26528130
http://dx.doi.org/10.3389/fncel.2015.00397

Ejemplares similares